These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15045867)

  • 1. [Current data on interferon therapy of multiple sclerosis in patients at developmental age].
    Smigielska-Kuzia J; Sobaniec W; Kułak W; Boćkowski L; Wołk M; Sołowiej E; Artemowicz B
    Neurol Neurochir Pol; 2004; 38(1 Suppl 1):S45-51. PubMed ID: 15045867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of interferon beta in relapsing-remitting multiple sclerosis.
    Etheridge LJ; Beverley DW; Ferrie C; McManus E
    Arch Dis Child; 2004 Aug; 89(8):789-91. PubMed ID: 15269086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Early immunomodulatory treatment of multiple sclerosis: pros and cons].
    Wender M
    Neurol Neurochir Pol; 2003; 37(4):777-82. PubMed ID: 14746238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Magnetic resonance angiography in multiple sclerosis].
    Pati DV; Vorobeĭchik G
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(12):53-7. PubMed ID: 10629934
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management.
    Stuart WH
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S19-25. PubMed ID: 15253686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A short history of beta-interferon therapy of multiple sclerosis].
    Stock G; Horowski R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-beta1a treatment for multiple sclerosis.
    Sandberg-Wollheim M
    Expert Rev Neurother; 2005 Jan; 5(1):25-34. PubMed ID: 15853471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Betaseron: a breakthrough treatment for multiple sclerosis.
    Morrison W; Nelson J
    Can Nurse; 1996 Oct; 92(9):38-41. PubMed ID: 9118060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interferon beta and copolymer-1: mechanism of action and clinical effects in multiple sclerosis].
    Losy J
    Neurol Neurochir Pol; 2000; 34(3 Suppl):63-9. PubMed ID: 10983302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
    Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
    Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seeing injectable ms therapies differently: they are more similar than different.
    Johnson KP; Fox RJ; Arnold DL
    Neurology; 2010 Feb; 74(8):702. PubMed ID: 20177129
    [No Abstract]   [Full Text] [Related]  

  • 12. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
    Correale J; Cristiano E
    Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis.
    Banwell B; Reder AT; Krupp L; Tenembaum S; Eraksoy M; Alexey B; Pohl D; Freedman M; Schelensky L; Antonijevic I
    Neurology; 2006 Feb; 66(4):472-6. PubMed ID: 16505297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
    Bykova OV; Kuzenkova LM; Maslova OI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):29-33. PubMed ID: 17069059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Still no evidence on the efficacy of immunomodulatory therapy in reducing functional impairment in multiple sclerosis].
    Vermeulen M
    Ned Tijdschr Geneeskd; 2007 Apr; 151(15):850-1. PubMed ID: 17472114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.
    Goodin DS; Bates D
    Mult Scler; 2009 Oct; 15(10):1175-82. PubMed ID: 19737851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis.
    Guerrero AL; Tejero MA; Gutiérrez F; Martín-Polo J; Iglesias F; Laherran E; Martín-Serradilla JI; Merino S
    Neurologia; 2011 Apr; 26(3):137-42. PubMed ID: 21163235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of interferon beta in the treatment of multiple sclerosis].
    Seeldrayers P
    Rev Med Brux; 1999 Sep; 20(4):A264-7. PubMed ID: 10523902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The BCTRIMS expanded consensus on treatment of multiple sclerosis: II. The evidences for the use of glucocorticoids and immunomodulatory treatments].
    Moreira MA; Lana-Peixoto MA; Callegaro D; Haussen SR; Gama PD; Gabbai AA; Rocha FC; Lino AM;
    Arq Neuropsiquiatr; 2002 Sep; 60(3-B):875-80. PubMed ID: 12364966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment with beta-interferon should be started already after the first attack of MS].
    Söderström M
    Lakartidningen; 2001 Feb; 98(6):587-90, 593-4. PubMed ID: 11475246
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.